DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0148354 A1 Campana Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0148354 A1 Campana Et Al US 20140148354A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0148354 A1 Campana et al. (43) Pub. Date: May 29, 2014 (54) METHODS AND COMPOSITIONS FOR Publication Classification IDENTIFYING MINIMIAL RESIDUAL DISEASE IN ACUTELYMPHOBLASTIC (51) Int. Cl. LEUKEMA CI2O I/68 (2006.01) (75) Inventors: Dario Campana, Kent Vale (SG); (52) U.S. Cl. Elaine Coustan-Smith, Kent Vale (SG) CPC .................................... CI2O I/6886 (2013.01) (73) Assignee: ST. JUDE CHILDREN'S RESEARCH USPC .............................................. 506/9; 435/7.21 HOSPITAL, Memphis, TN (US) (21) Appl. No.: 14/005,921 (57) ABSTRACT (22) PCT Filed: Mar. 14, 2012 (86). PCT No.: PCT/US12/28993 This invention provides methods and kits for diagnosing, ascertaining the clinical course of minimal residual disease S371 (c)(1), associated with acute lymphoblastic leukemia (ALL). Spe (2), (4) Date: Oct. 2, 2013 cifically the invention provides methods and kits useful in the Related U.S. Application Data diagnosis and determination of clinical parameters associated (60) Provisional application No. 61/470,056, filed on Mar. with diseases associated with ALL based on patterns of Sur 31, 2011. face marker expression unique to ALL. Patent Application Publication May 29, 2014 Sheet 1 of 6 US 2014/0148354 A1 PCO.0001 P40.001 1 OOO BCL2 HSPB 1 CD304 CD164 CD73 CD3OOA CD200 P&O.01 1000 N - N - N L. N. L. N. L. CD72 CD130 CD37 CD86 CD97 CD123 FIGURE 1 Patent Application Publication May 29, 2014 Sheet 2 of 6 US 2014/O148354 A1 10000 1OOO 1OOO L N. L. N. L N EPOR (CD69 CD 132 CD83 CD120 L13RA CD62L FIGURE 2 Patent Application Publication May 29, 2014 Sheet 3 of 6 US 2014/O148354 A1 O.O1 0.1 1 10 Flow Cytometry (%) FIGURE 3 Patent Application Publication May 29, 2014 Sheet 4 of 6 US 2014/0148354 A1 Pt. 2 500 BC2 O HSPB1 HSPB 400 KX CD200 CD86 300 {0 CD123 CD200 i CD97 CD102 200 : CD99 O O 19 42 O 19 42 Days from diagnosis Days from diagnosis Pt. 3 Pt. 4 300 500 CD123 {d CD123 CD300A 400 O CD97 200 300 t 200 100 100 O 19 42 O 19 42 Days from diagnosis Days from diagnosis FIGURE 4 Patent Application Publication May 29, 2014 Sheet 5 of 6 US 2014/O148354 A1 S S. S. S. O O i Hyperdiploid ETV6-RUNX1 TCF3-PBX1 BCR-ABL1. MLL Other b 20 4o 60 80 150 % of cases with differential expression FIGURE 5 Patent Application Publication May 29, 2014 Sheet 6 of 6 US 2014/O148354 A1 MRD = 0.01% CD86 CD97 CD38 CD97 CD38 CD86 CD97 CD38 FIGURE 6 US 2014/0148354 A1 May 29, 2014 METHODS AND COMPOSITIONS FOR 116:1165-1176). MRD measurements are also clinically use IDENTIFYING MINIMIAL RESIDUAL ful in patients with relapsed ALL who achieve a second DISEASE IN ACUTELYMPHOBLASTIC remission (Coustan-Smith et al. (2004) Leukemia 18:499 LEUKEMA 504; Paganinet al. (2008) Leukemia. 22:2193-2200; Raetz et al. (2008) J Clin. Oncol. 26:3971-3978), can help optimize STATEMENT REGARDING FEDERALLY the timing of hematopoietic stem cell transplantation (Bader SPONSORED RESEARCH ORDEVELOPMENT et al. (2009).J Clin Oncol. 27:377-384), and guide decisions 0001. This invention was made with support under United about donor lymphocyte infusion post-transplant (Lankester et al. (2010) Leukemia. 24: 1462-1469). States Government Grant CA60419 awarded by the National 0007. Among methods for detecting MRD in ALL, PCR Institutes of Health. The United States Government has cer amplification of antigen-receptor genes has proven to be valu tain rights in this invention. able and has been extensively standardized (Bruggemann, REFERENCE TO SEQUENCE LISTING M., et al. (2010) Leukemia. 24:521-535) but the technical SUBMITTED ELECTRONICALLY expertise and instrumentation required limit its application to specialized centers. PCR amplification of fusion transcripts 0002 The official copy of the sequence listing is submitted may also provide useful clinical information but its applica electronically via EFS-Web as an ASCII formatted sequence bility in ALL is restricted by the fact that molecular targets listing with a file named 415313SEQLIST.txt, created on currently adaptable to routine MRD studies are present in Mar. 6, 2012, and having a size of 225,858 bytes and is filed only a minority of patients. Id. Flow cytometric detection of concurrently with the specification. The sequence listing con leukemia-specific markers has been shown to predict out tained in this ASCII formatted document is part of the speci come in numerous clinical correlative studies (Coustan fication and is herein incorporated by reference in its entirety. Smithetal. (1998) Lancet. 351:550-554; Coustan-Smithetal. (2000) Blood. 96:2691-2696; Dworzak et al. (2002) Blood. FIELD OF THE INVENTION 99: 1952-1958; Borowitz, et al. (2008) Blood. 111:5477 0003. This invention relates generally to the detection of 5485; Basso et al. (2009) J Clin Oncol. 27:5168-5174; minimal residual disease in patients with acute lymphoblastic Krampera et al. (2003) BrJ Haematol 120:74-79; Vidriales et leukemia (ALL) and, more specifically, to a method to al. (2003) Blood 101:4695-4700; Hollowieckietal. (2008) Br: improve minimal residual disease monitoring for risk assign J. Haematol. 142:227-237). The method holds potential for ment and selection of therapeutic regimens. wider applicability than molecular techniques because flow cytometric methods for leukemia diagnosis are already estab BACKGROUND OF THE INVENTION lished at most cancer centers worldwide (Campana (2009) Hematol. Oncol Clin North Am. 23:1083-98, vii). 0004 Leukemia relapse is the major cause of treatment 0008 MRD studies by flow cytometry rely on panels of failure for patients with acute lymphoblastic leukemia (ALL) antibodies to define unique immunophenotypic signatures of (Pui et al. (2009) N Engl J Med. 360:2730-2741; Gokbuget leukemic cells which must distinguish leukemic blasts from and Hoelzer (2009) Semin. Hematol. 46:64-75; and Faderlet their normal counterparts, the CD19+ CD10+ lymphoid pro al. (2010) Cancer: 116:1165-1176). Relapse originates from genitors of the bone marrow (“hematogones') (Campana leukemic cells that are resistant to chemotherapy but become undetectable after initial treatment in most cases. Neverthe (2009) Hematol. Oncol Clin North Am. 23:1083-98, vii; less, methods more sensitive than microscopic examination Bruggemann et al. (2010) Leukemia. 24:521-535; McKenna can demonstrate leukemic cells in a proportion of Samples et al. (2001) Blood. 98:2498-2507; Lucio et al. (2001) Leu with no morphologic evidence of leukemia, a finding termed kemia. 15:1185-1192). “minimal residual disease (MRD)' (Campana (2009) Hema 0009 Standard four-color flow cytometry can detect one tol. Oncol Clin North Am. 23:1083-98, vii). leukemic cell in up to 10,000 normal bone marrow or periph 0005 MRD is currently the most powerful prognostic eral blood cells but this task typically requires considerable indicator in childhood ALL (Cave etal. (1998) N Engl.J.Med. interpretative expertise. Therefore, identification of new leu 339:591-598; Coustan-Smith et al. (1998) Lancet. 351:550 kemia markers that are easily detectable and are stably 554; van Dongen et al. (1998) Lancet. 352:1731-1738; Cous expressed in a large proportion of ALL cases could simplify tan-Smith et al. (2000) Blood. 96:2691-2696; Dworzak et al. the application of MRD studies, and help extend their benefit (2002) Blood. 99:1952-1958; Nyvold et al. (2002) Blood. to all patients and enhance the sensitivity of MRD detection. 99:1253-1258; Zhou et al. (2007) Blood. 110:1607-1611; BRIEF SUMMARY OF THE INVENTION Borowitz et al. (2008) Blood. 111:5477-5485. Basso et al. (2009) J Clin Oncol. 27:5168-5174; Canter et al. (2010) 0010 Methods and compositions are provided for identi Blood. 115:3206-3214; Stow et al. (2010) Blood. 115:4657 fying patients with minimal residual disease. The diagnostic 4663). There is strong evidence Supporting its prognostic methods generally comprise contacting a specimen from a significance in adult ALL (Krampera et al. (2003) Bru Hae patient with a plurality of probes, wherein each of said probes matol. 120:74-79; Vidriales, et al. (2003) Blood. 101:4695 specifically binds to a distinct marker, wherein a first probe 4700; Raffet al. (2007) Blood. 109:910-915; Hollowiecki et specifically binds to CD19, a second probe specifically binds al. (2008) Br. J. Haematol. 142:227-237; Bassan et al. (2009) to CD10, a third probe specifically binds to CD34, a fourth Blood. 113:4153-4162). probe specifically binds to CD45, and at least two additional 0006 Thus, MRD monitoring has been introduced into probes that specifically binds to any two of CD38, CD24, many contemporary treatment protocols for risk assignment CD44, CD58, CD73, CD15, CD200, CD66c, CD123, CD86, and selection of therapeutic regimens (Pui et al. (2009) N CD72, CD13, CD33, CD79b, HSPB1, BCL2, CD164, EnglJ Med. 360:2730-2741; Gokbuget and Hoelzer. (2009) CD304, CD97, CD99, CD102, or CD3.00a. The complex Semin. Hematol. 46:64-75; and Faderl et al. (2010) Cancer. formed between each of the probes and their marker is US 2014/0148354 A1 May 29, 2014 detected and a value is generated corresponding to an expres ments are provided so that this disclosure will satisfy appli sion level of each of said marker. An expression profile is cable legal requirements. Like numbers refer to like elements generated by combining the expression level values. In Such throughout. methods, the expression of CD19, CD10, CD34 and CD45 0020 Many modifications and other embodiments of the and a modulated level of at least two of CD38, CD24, CD44, inventions set forth herein will come to mind to one skilled in CD58, CD73, CD15, CD200, CD66c, CD123, CD86, CD72, the art to which these inventions pertain having the benefit of CD13, CD33, CD79b, HSPB1, BCL2, CD164, CD304, the teachings presented in the foregoing descriptions and the CD97, CD99, CD102, or CD300a relative to a normal control associated drawings.
Load more

Recommended publications
  • Imm Catalog.Pdf
    $ Gene Symbol A B 3 C 4 D 9 E 10 F 11 G 12 H 13 I 14 J. K 17 L 18 M 19 N 20 O. P 22 R 26 S 27 T 30 U 32 V. W. X. Y. Z 33 A ® ® Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera Gene Symbol Gene ID Antibody Monoclonal Antibody Polyclonal MaxPab Full-length Protein Partial-length Protein Antibody Pair KIt siRNA/Chimera A1CF 29974 ● ● ADAMTS13 11093 ● ● ● ● ● A2M 2 ● ● ● ● ● ● ADAMTS20 80070 ● AACS 65985 ● ● ● ADAMTS5 11096 ● ● ● AANAT 15 ● ● ADAMTS8 11095 ● ● ● ● AATF 26574 ● ● ● ● ● ADAMTSL2 9719 ● AATK 9625 ● ● ● ● ADAMTSL4 54507 ● ● ABCA1 19 ● ● ● ● ● ADAR 103 ● ● ABCA5 23461 ● ● ADARB1 104 ● ● ● ● ABCA7 10347 ● ADARB2 105 ● ABCB9 23457 ● ● ● ● ● ADAT1 23536 ● ● ABCC4 10257 ● ● ● ● ADAT2 134637 ● ● ABCC5 10057 ● ● ● ● ● ADAT3 113179 ● ● ● ABCC8 6833 ● ● ● ● ADCY10 55811 ● ● ABCD2 225 ● ADD1 118 ● ● ● ● ● ● ABCD4 5826 ● ● ● ADD3 120 ● ● ● ABCG1 9619 ● ● ● ● ● ADH5 128 ● ● ● ● ● ● ABL1 25 ● ● ADIPOQ 9370 ● ● ● ● ● ABL2 27 ● ● ● ● ● ADK 132 ● ● ● ● ● ABO 28 ● ● ADM 133 ● ● ● ABP1 26 ● ● ● ● ● ADNP 23394 ● ● ● ● ABR 29 ● ● ● ● ● ADORA1 134 ● ● ACAA2 10449 ● ● ● ● ADORA2A 135 ● ● ● ● ● ● ● ACAN 176 ● ● ● ● ● ● ADORA2B 136 ● ● ACE 1636 ● ● ● ● ADRA1A 148 ● ● ● ● ACE2 59272 ● ● ADRA1B 147 ● ● ACER2 340485 ● ADRA2A 150 ● ● ACHE 43 ● ● ● ● ● ● ADRB1 153 ● ● ACIN1 22985 ● ● ● ADRB2 154 ● ● ● ● ● ACOX1 51 ● ● ● ● ● ADRB3 155 ● ● ● ● ACP5 54 ● ● ● ● ● ● ● ADRBK1 156 ● ● ● ● ACSF2 80221 ● ● ADRM1 11047 ● ● ● ● ACSF3 197322 ● ● AEBP1 165 ● ● ● ● ACSL4 2182 ●
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Was There a Custom of Distributing the Booty in the Crusades of the Thirteenth Century?
    Benjámin Borbás WAS THERE A CUSTOM OF DISTRIBUTING THE BOOTY IN THE CRUSADES OF THE THIRTEENTH CENTURY? MA Thesis in Late Antique, Medieval and Early Modern Studies Central European University Budapest May 2019 CEU eTD Collection WAS THERE A CUSTOM OF DISTRIBUTING THE BOOTY IN THE CRUSADES OF THE THIRTEENTH CENTURY? by Benjámin Borbás (Hungary) Thesis submitted to the Department of Medieval Studies, Central European University, Budapest, in partial fulfillment of the requirements of the Master of Arts degree in Late Antique, Medieval and Early Modern Studies. Accepted in conformance with the standards of the CEU. ____________________________________________ Chair, Examination Committee ____________________________________________ Thesis Supervisor ____________________________________________ Examiner ____________________________________________ Examiner CEU eTD Collection Budapest May 2019 WAS THERE A CUSTOM OF DISTRIBUTING THE BOOTY IN THE CRUSADES OF THE THIRTEENTH CENTURY? by Benjámin Borbás (Hungary) Thesis submitted to the Department of Medieval Studies, Central European University, Budapest, in partial fulfillment of the requirements of the Master of Arts degree in Late Antique, Medieval and Early Modern Studies. Accepted in conformance with the standards of the CEU. ____________________________________________ External Reader Budapest May 2019 CEU eTD Collection WAS THERE A CUSTOM OF DISTRIBUTING THE BOOTY IN THE CRUSADES OF THE THIRTEENTH CENTURY? by Benjámin Borbás (Hungary) Thesis submitted to the Department of Medieval Studies,
    [Show full text]
  • North Fork of the St. Lucie River Floodplain Vegetation Technical Report
    NORTH FORK ST. LUCIE RIVER FLOODPLAIN VEGETATION TECHNICAL REPORT WR-2015-005 Coastal Ecosystem Section Applied Sciences Bureau Water Resources Division South Florida Water Management District Final Report July 2015 i Resources Division North Fork of the St. Lucie River Floodplain Vegetation Technical Report ACKNOWLEDGEMENTS This document is the result of a cooperative effort between the Coastal Ecosystems Section of South Florida Water Management District (SFWMD) and the Florida Department of Environmental Protection (FDEP), Florida Park Service (FPS) at the Savannas Preserve State Park in Jensen Beach, Florida and the Indian River Lagoon Aquatic Preserve Office in Fort Pierce, Florida. The principle author of this document was as follows: Marion Hedgepeth SFWMD The following staff contributed to the completion of this report: Cecilia Conrad SFWMD (retired) Jason Godin SFWMD Detong Sun SFWMD Yongshan Wan SFWMD We would like to acknowledge the contributions of Christine Lockhart of Habitat Specialist Inc. with regards to the pre-vegetation plant survey, reference collection established for this project, and for her assistance with plant identifications. We are especially grateful to Christopher Vandello of the Savannas Preserve State Park and Laura Herren and Brian Sharpe of the FDEP Indian River Lagoon Aquatic Preserves Office for their assistance in establishing the vegetation transects and conducting the field studies. And, we would like to recognize other field assistance from Mayra Ashton, Barbara Welch, and Caroline Hanes of SFWMD. Also, we would like to thank Kin Chuirazzi for performing a technical review of the document. ii North Fork of the St. Lucie River Floodplain Vegetation Technical Report TABLE OF CONTENTS Acknowledgements ..........................................................................................................................ii List of Tables ...............................................................................................................................
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Cleveland Clinic Laboratories
    Cleveland Clinic Laboratories Technical Update • May 2014 Cleveland Clinic Laboratories is dedicated to keeping you updated and informed about recent testing changes. That's why we are happy to provide this technical update on a monthly basis. Recently changed tests are bolded, and could include revisions to methodology, reference range, days performed or CPT code. For your convenience, tests are listed alphabetically and the order and billing codes are provided. If you wish to compare the new information with previous test demographics, refer to the Test Directory, which can be accessed at clevelandcliniclabs.com. Deleted tests and new tests are listed separately. Please update your database as necessary. For additional detail, contact Client Services at 216.444.5755 or 800.628.6816 or via email at [email protected]. Days Performed/Reported Specimen Requirement Special InformationComponent Change Test Discontinued Reference Range Test Update Name Change Methodology Order CodeBiling Code New Test Page # Summary of Changes CPT by Test Name 3 5-Hydroxyindolacetic Acid, Urine 3 11-Deoxycorticosterone Qt, Serum / Plasma 3 25-Hydroxyvitamin D2 and D3, Serum 9 Alpha-1 Antitrypsin (SERPINA1) Targeted Genotyping 3 Alpha-1-Antitrypsin Clearance 3 Alpha-1-Antitrypsin, Stool 3 Anti IgA Antibody 3 Anti Mullerian Hormone 3 Beta Galactosidase, Leukocytes 4 Bioavailable Testosterone / SHBG, Female & Child 4 BK Virus Quantitation, Urine 12 Buprenorphine & Metabolite, Confirmation / Quant, Urine 9 Buprenorphine Quant, Urine 4 Carnitine Free & Total,
    [Show full text]
  • Table 2. Significant
    Table 2. Significant (Q < 0.05 and |d | > 0.5) transcripts from the meta-analysis Gene Chr Mb Gene Name Affy ProbeSet cDNA_IDs d HAP/LAP d HAP/LAP d d IS Average d Ztest P values Q-value Symbol ID (study #5) 1 2 STS B2m 2 122 beta-2 microglobulin 1452428_a_at AI848245 1.75334941 4 3.2 4 3.2316485 1.07398E-09 5.69E-08 Man2b1 8 84.4 mannosidase 2, alpha B1 1416340_a_at H4049B01 3.75722111 3.87309653 2.1 1.6 2.84852656 5.32443E-07 1.58E-05 1110032A03Rik 9 50.9 RIKEN cDNA 1110032A03 gene 1417211_a_at H4035E05 4 1.66015788 4 1.7 2.82772795 2.94266E-05 0.000527 NA 9 48.5 --- 1456111_at 3.43701477 1.85785922 4 2 2.8237185 9.97969E-08 3.48E-06 Scn4b 9 45.3 Sodium channel, type IV, beta 1434008_at AI844796 3.79536664 1.63774235 3.3 2.3 2.75319499 1.48057E-08 6.21E-07 polypeptide Gadd45gip1 8 84.1 RIKEN cDNA 2310040G17 gene 1417619_at 4 3.38875643 1.4 2 2.69163229 8.84279E-06 0.0001904 BC056474 15 12.1 Mus musculus cDNA clone 1424117_at H3030A06 3.95752801 2.42838452 1.9 2.2 2.62132809 1.3344E-08 5.66E-07 MGC:67360 IMAGE:6823629, complete cds NA 4 153 guanine nucleotide binding protein, 1454696_at -3.46081884 -4 -1.3 -1.6 -2.6026947 8.58458E-05 0.0012617 beta 1 Gnb1 4 153 guanine nucleotide binding protein, 1417432_a_at H3094D02 -3.13334396 -4 -1.6 -1.7 -2.5946297 1.04542E-05 0.0002202 beta 1 Gadd45gip1 8 84.1 RAD23a homolog (S.
    [Show full text]
  • Monoclonal Antibodies Against Cd30 Lacking In
    (19) TZZ_97688¥_T (11) EP 1 976 883 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07K 16/28 (2006.01) A61P 35/00 (2006.01) 03.10.2012 Bulletin 2012/40 A61P 37/00 (2006.01) (21) Application number: 07718000.8 (86) International application number: PCT/US2007/001451 (22) Date of filing: 17.01.2007 (87) International publication number: WO 2007/084672 (26.07.2007 Gazette 2007/30) (54) MONOCLONAL ANTIBODIES AGAINST CD30 LACKING IN FUCOSYL AND XYLOSYL RESIDUES MONOKLONALE ANTIKÖRPER GEGEN CD30 OHNE FUCOSYL- UND XYLOSYLRESTE ANTICORPS MONOCLONAUX ANTI-CD30 DEPOURVUS DE RESIDUS FUCOSYL ET XYLOSYL (84) Designated Contracting States: • WANG, Ming-Bo AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Canberra Australian Capital Territory 2617 (AU) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Tuxworth, Pamela M. Designated Extension States: J A Kemp RS 14 South Square Gray’s Inn (30) Priority: 17.01.2006 US 759298 P London WC1R 5JJ (GB) 07.04.2006 US 790373 P 11.04.2006 US 791178 P (56) References cited: 09.06.2006 US 812702 P WO-A-03/059282 US-A1- 2004 261 148 11.08.2006 US 837202 P 11.08.2006 US 836998 P • P. BORCHMANN ET AL.: "The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity (43) Date of publication of application: against malignant lymphoma." BLOOD, vol. 102, 08.10.2008 Bulletin 2008/41 no.
    [Show full text]
  • Overexpressed Nup88 Stabilized Through Interaction with Nup62 Promotes NFB
    bioRxiv preprint doi: https://doi.org/10.1101/2020.04.27.063057; this version posted May 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Overexpressed Nup88 stabilized through interaction with Nup62 promotes NFB dependent pathways in cancer Usha Singh1, Atul Samaiya2, and Ram Kumar Mishra1,* 1 Nups and Sumo Biology Group, Department of Biological Sciences, Indian Institute of Science Education and Research (IISER) Bhopal, Madhya Pradesh, 462066, India. 2 Department of Surgical Oncology, Bansal Hospital, Bhopal, Madhya Pradesh, 462016, India * To whom correspondence should be addressed. Corresponding Author: Phone – +91-755-2691407 Fax - +91-755-2692392 Email- [email protected] Keywords Nup88; NFB; Head and neck cancer; ubiquitination; cell proliferation; inflammation 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.04.27.063057; this version posted May 4, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Nuclear pores control nucleo-cytoplasmic trafficking and directly or indirectly regulate vital cellular processes. Nup88, important for Crm1 mediated nuclear export process, is overexpressed in many cancers. A positive correlation exists between progressive stages of cancer and Nup88 expression. However, links between Nup88 overexpression and head and neck cancer are insignificant, and mechanistic details are non-existent. Here, we report that Nup88 exhibits positive correlation in head and neck cancer in addition to elevated Nup62 levels. We demonstrate that Nup88 interacts with Nup62 in a cell-cycle and glycosylation independent manner.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Regulatory Mechanisms of Apoptosis in Regularly Dividing Cells
    Cell Health and Cytoskeleton Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Regulatory mechanisms of apoptosis in regularly dividing cells Ribal S Darwish Abstract: The balance between cell survival and death is essential for normal development and Department of Anesthesiology, homeostasis of organisms. Apoptosis is a distinct type of cell death with ultrastructural features Division of Critical Care Medicine, that are consistent with an active, inherently controlled process. Abnormalities and dysregulation University of Maryland Medical of apoptosis contribute to the pathophysiology of multiple disease processes. Apoptosis is strictly Center, Baltimore, Maryland, USA regulated by several positive and negative feedback mechanisms that regulate cell death and determine the final outcome after cell exposure to apoptotic stimuli. Mitochondria and caspases are central components of the regulatory mechanisms of apoptosis. Recently, noncaspase pathways of apoptosis have been explored through the studies of apoptosis-inducing factor and endonu- clease G. Multiple difficulties in the apoptosis research relate to apoptosis detection and imaging. For personal use only. This article reviews current understanding of the regulatory mechanisms of apoptosis. Keywords: caspases, apoptosis-inducing factor, apoptosis inhibitory proteins, cytochrome c, mitochondria Introduction Apoptosis is a distinct type of cell death with ultrastructural features that are con- sistent with an active, inherently controlled process, and it is a part of the necrobio- sis, a process that is essential in maintaining tissue homeostasis. The concept that cells must be lost from the normal tissues to balance their mitotic activity was first proposed by the German anatomist Ludwig Graper,1 who proposed that chromolysis must exist in the cells that will be eliminated.
    [Show full text]